Treatment outcome and safety of anti-PD-1 antibody against elderly non-small cell lung cancer.

被引：0
|
作者：
Sakatani, Toshio
Saihara, Aya
Ikushima, Hiroaki
Takeshima, Hideyuki
Taniguchi, Yuri
Hojo, Masayuki
Usui, Kazuhiro
机构：
[1] NTT Med Ctr Tokyo, Tokyo, Japan
[2] Kanto Med Ctr NTT EC, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e14249
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14249
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Anti-PD-1 Combination Therapy as Second Line Treatment or Beyond in Patients with Advanced Non-Small Cell Lung Cancer
    Zhang, F.
    Huang, D.
    Li, L.
    Ma, J.
    Wang, J.
    Jiao, S.
    Hu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1055 - S1055
  • [42] Serum antibody against NY-ESO-1 and XAGE1 predicts clinical responses to anti-PD-1 therapy in non-small cell lung cancer
    Kurose, Koji
    Ohue, Yoshihiro
    Karasaki, Takahiro
    Futami, Junichiro
    Irei, Isao
    Masuda, Takeshi
    Fukuda, Masaaki
    Kinoshita, Akitoshi
    Matsushita, Hirokazu
    Shimizu, Katsuhiko
    Yamaguchi, Hiroyuki
    Fukuda, Minoru
    Kakimi, Kazuhiro
    Oka, Mikio
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [43] Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer
    Zhao Lingdi
    Ma Baozhen
    Yang Yonghao
    Li Tiepeng
    Han Lu
    Gao Quanli
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [44] Prognostic Nomogram for Advanced Non-Small Cell Lung Cancer Patients Treated With Anti-PD-1 Inhibitors
    Chai, R.
    Fan, Y.
    Zhao, J.
    He, F.
    Han, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S254 - S255
  • [45] Predictive immunological markers of anti-PD-1/PD-L1 therapy efficacy in non-small cell lung cancer
    Musaelyan, A. A.
    Lapin, S. V.
    Urtenova, M. A.
    Chistyakov, I. V.
    Nazarov, V. D.
    Akopov, A. L.
    Orlov, S. V.
    ANNALS OF ONCOLOGY, 2021, 32 : S1382 - S1382
  • [46] Clinical Characteristics of Acquired Resistance with Anti-PD-1/PD-L1 in Non-Small Cell Lung Cancer (NSCLC)
    Shah, Shalin
    Wood, Kevin
    Brisson, Ryan
    Karrison, Theodore
    Hensing, Thomas
    Luke, Jason J.
    Patel, Jyoti D.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S310 - S310
  • [47] Immunological markers of outcome of non-small cell lung cancer.
    Potter, DA
    Amin, C
    Mohiuddin, A
    Badve, S
    Davidson, D
    Kesler, K
    Hanna, N
    Edenberg, H
    Einhorn, L
    Mitra, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 678S - 678S
  • [48] Serum immune modulators during the first cycle of anti-PD-1 antibody therapy in non-small cell lung cancer: Perforin as a biomarker
    Ota, Takayo
    Fukui, Tomoya
    Nakahara, Yoshiro
    Takeda, Takayuki
    Uchino, Junji
    Mouri, Takako
    Kudo, Keita
    Nakajima, Saki
    Suzumura, Tomohiro
    Fukuoka, Masahiro
    THORACIC CANCER, 2020, 11 (11) : 3223 - 3233
  • [49] ALBUMIN-GLOBULIN RATIO IS A PREDICTIVE BIOMARKER OF ANTITUMOR EFFECT OF ANTI-PD-1 ANTIBODY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Nakanishi, Yu
    Masuda, Takeshi
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Nakashima, Taku
    Miyamoto, Shintaro
    Iwamoto, Hiroshi
    Fujitaka, Kazunori
    Hamada, Hironobu
    Hattori, Noboru
    RESPIROLOGY, 2019, 24 : 191 - 191
  • [50] Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer
    Nakanishi, Yu
    Masuda, Takeshi
    Yamaguchi, Kakuhiro
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Mimae, Takahiro
    Nakashima, Taku
    Miyamoto, Shintaro
    Tsutani, Yasuhiro
    Iwamoto, Hiroshi
    Fujitaka, Kazunori
    Miyata, Yoshihiro
    Hamada, Hironobu
    Okada, Morihito
    Hattori, Noboru
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (01) : 74 - 81
12345